Hemab Therapeutics Holdings, Inc. (COAG) Stock Price & Analysis
Hemab Therapeutics Holdings, Inc. (COAG) closed at USD 42.81 on Monday, November 9, 2026, down 12.67% on the day. The US market is currently closed (pre-market); this is not a live price.
The prior close was USD 49.02; the Nov 9, 2026 session ranged USD 42.63–50.22 on volume of 1,095,821 shares. Market capitalization is $2.00B, with a 52-week range of USD 23–55.42 (NMS). Source: Nexqual, retrieved November 10, 2026 at 12:21 UTC.
Also available as compact Markdown for AI agents: nexqual.com/COAG.md
Key facts (COAG)
- Insider open-market purchases, last ~7 months: 5 Form 4 filings, $55.5M; 0 by opportunistic insiders, 0 by routine insiders.
- Analysts: Buy (mean 1.83 on a 1–5 scale) (6 analysts), mean target USD 62.67 (range 58–70).
- Total return with dividends: 1Y +25.9% vs S&P 500 +11.7%; 5Y +25.9% vs S&P 500 +72.2%.
- Next earnings: 2026-11-10, EPS estimate USD -0.52, revenue estimate $0K. All companies reporting that day: https://nexqual.com/earnings/2026-11-10
- Dividend: COAG paid no cash dividend in the last five years.
- Short interest: 3,161,285 shares (as of 2026-10-15), 5.3 days to cover.
Valuation (price ÷ last four quarters, through Jun 30, 2026) (COAG)
P/B 4.4x · FCF yield -3.64% · Earnings yield -3.72%
Insider purchases (SEC Form 4, open-market, last ~7 months) (COAG)
5 purchases, $55.5M. Private placements, offerings, dividend reinvestment and employee stock purchase plan buys are excluded.
| Trade date | Insider | Role | Shares | Value | Avg price | Insider type |
|---|---|---|---|---|---|---|
| 2026-06-15…2026-06-16 | Ra Capital Management, L.P. | 67,669 | $1.7M | 24.97 | Too little history (no open-market trades in 2023–2025) | |
| 2026-05-19…2026-05-20 | Ra Capital Management, L.P. | 4,798 | $120K | 24.96 | Too little history (no open-market trades in 2023–2025) | |
| 2026-05-12 | Ra Capital Management, L.P. | 6,387 | $159K | 24.9 | Too little history (no open-market trades in 2023–2025) | |
| 2026-05-07…2026-05-11 | Ra Capital Management, L.P. | 51,258 | $1.3M | 24.75 | Too little history (no open-market trades in 2023–2025) | |
| 2026-05-04…2026-05-06 | Ra Capital Management, L.P. | Director | 2,840,429 | $52.2M | 18.39 | Too little history (no open-market trades in 2023–2025) |
Insider type follows Cohen, Malloy & Pomorski (Journal of Finance, 2012). An insider who traded the stock in the same calendar month in each of the past three years is a routine trader; one who traded in each of those years without such a pattern is an opportunistic trader. In their study, trades by opportunistic insiders predicted future returns and trades by routine insiders did not. Counts open-market purchases and sales only (SEC Form 4 codes P and S) by that insider in that company. Not investment advice.
Analysts (COAG)
Consensus Buy (mean 1.83 on a 1–5 scale), 6 analysts; mean target USD 62.67 (low 58, high 70).
Rating changes, last 120 days:
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-11-09 | LifeSci Capital | Initiated | Outperform | $65 |
| 2026-10-15 | JP Morgan | Initiated | Overweight | $70 |
| 2026-10-12 | Rodman & Renshaw | Initiated | Buy | $56 |
| 2026-08-12 | Wedbush | Target raised | Outperform | $55 → $64 |
| 2026-08-11 | HC Wainwright & Co. | Target raised | Buy | $52 → $60 |
| 2026-07-13 | Jefferies | Target raised | Buy | $39 → $47 |
| 2026-07-13 | Wedbush | Target raised | Outperform | $42 → $55 |
Total return (dividends reinvested) (COAG)
| 1Y (from 2026-05-01) | 5Y (from 2026-04-27) | |
|---|---|---|
| Total return | +25.9% | +25.9% |
| S&P 500 (SPY) | +11.7% | +72.2% |
| Per year | — | — |
| Volatility (annualized) | 90.2% | 95.4% |
| Max drawdown | -48.4% (Aug 2026→Oct 2026) | -45.3% (Aug 2026→Oct 2026) |
Dividends (COAG)
COAG paid no cash dividend in the last five years.
Short interest (COAG)
3,161,285 shares sold short, as of Oct 15, 2026 (exchange short-interest report, published about twice a month). Prior report (Sep 15, 2026): 2,641,038 shares (+19.7%). Days to cover: 5.3 (short shares ÷ average daily volume).
COAG earnings history and stock reaction
| Results filed | Quarter | EPS | Consensus | Surprise | Stock reaction |
|---|---|---|---|---|---|
| — | Quarter ended Jun 30, 2026 | −$0.80 | −$0.82 | Beat +2.4% | — |
| — | Quarter ended Mar 31, 2026 | −$23.98 | — | — | — |
EPS as reported against the analyst consensus before the release; surprise uses the cent-rounded figures shown (in dollars when EPS and consensus have opposite signs). Stock reaction = close before the results to close after (the first close following a release after the bell or before the open).
COAG recent SEC filings (last 120 days)
| Filed | Form | What it says |
|---|---|---|
| Nov 10, 2026 | 8-K | Quarterly results |
| Nov 6, 2026 | Schedule 13G/A | FMR LLC, Abigail P. Johnson: 10.4% of shares, passive 5%+ holder (amended) |
| Sep 24, 2026 | 8-K | Director or executive officer change, or pay arrangement “On September 24, 2026, upon the recommendation of the Nominating and Corporate Governance Committee of the Board of Directors (the "Board") of Hemab Therapeutics Holdings, Inc. (the "Company"), the Board elected Keli Walbert to serve as a member of the Board, effective immediately. Ms. Walbert will serve as a Class I director with a term expiring at the 2027 annual meeting of stockholders and thereafter until her successor has been duly elected and qualified or until her earlier death, resignation or removal. The…” |
| Aug 14, 2026 | Schedule 13G | Novo Holdings A/S: 9.0% of shares, passive 5%+ holder |
| Aug 14, 2026 | Schedule 13G | Avoro Capital Advisors LLC, Avoro Ventures LLC: 7.1% of shares, passive 5%+ holder |
| Aug 12, 2026 | Schedule 13G | Capital International Investors: 7.7% of shares, passive 5%+ holder |
| Aug 11, 2026 | 10-Q | Quarterly report · period ended Jun 30, 2026 |
| Aug 11, 2026 | 8-K | Quarterly results |
| Aug 7, 2026 | Schedule 13G | Invus Public Equities, L.P., Invus Public Equities Advisors, LLC: 5.1% of shares, passive 5%+ holder |
| Aug 6, 2026 | Schedule 13G | FMR LLC, Abigail P. Johnson: 7.9% of shares, passive 5%+ holder |
| Aug 5, 2026 | Schedule 13G | Sofinnova Crossover II SLP, Sofinnova Partners SAS, a French corporation: 5.4% of shares, passive 5%+ holder |
Source: SEC EDGAR. Quotes are the opening words of each item as filed; each form links to the filing. Insider Form 4 filings are listed in the insider sections.
COAG company outlook (results filed Nov 10, 2026)
- “Across the single ascending dose cohorts, 8 of 9 evaluable patients had zero treated bleeds in the 28 days following HMB-002 dosing, with a mean ATBR of 1.6, compared with a baseline mean ATBR of 20.1 prior to treatment. The Company expects to report additional data from the trial at the 20th EAHAD (European Association for Haemophilia and Allied Disorders) Congress in February 2027.”
- “The Company will present these data as a poster at the 68th ASH Annual Meeting and Exposition on December 13, 2026, and expects initial clinical data from the ongoing Phase 1 trial in mid-2027.”
Quoted word-for-word from the SEC 8-K results press release.
COAG analyst estimates and revisions
| Period | EPS estimate | 90 days ago | Change | Revenue estimate | Analysts |
|---|---|---|---|---|---|
| Current quarter (ends Sep 2026) | $-0.52 | $-0.49 | −$0.03 | $0 | 5 |
| Next quarter (ends Dec 2026) | $-0.57 | $-0.58 | +$0.01 | $0 | 5 |
| Current fiscal year (ends Dec 2026) | $-3.11 | $-3.06 | −$0.05 | $0 | 5 |
| Next fiscal year (ends Dec 2027) | $-2.55 | $-2.51 | −$0.03 | $0 | 5 |
Key Statistics (as of November 10, 2026 at 12:21 UTC)
| Price | USD 42.81 |
|---|---|
| Change | ▼ 12.67% (down) |
| Previous Close | USD 49.02 |
| Open | USD 49.92 |
| Day Range | USD 42.63 – 50.22 |
| 52-Week Range | USD 23 – 55.42 |
| Volume | 1,095,821 shares |
| Market Cap | $2.00B |
| Exchange | NMS |
Technical Analysis (COAG)
Nexqual's technical model rates COAG "STRONG BUY" based on 5 bullish and 0 bearish signals across 127 daily candles, as of November 10, 2026 at 12:21 UTC.
| Overall Signal | STRONG BUY |
|---|---|
| RSI (14) | 58.03 (neutral) |
| vs SMA50 | Above (USD 37.46) |
| MACD | 2.74 (positive) |
Analyst Ratings (COAG)
Wall Street analysts rate COAG "Buy" based on 6 analysts, with a mean price target of USD 62.67 (range USD 58–70), per Nexqual as of November 10, 2026 at 12:21 UTC.
| Consensus Rating | Buy |
|---|---|
| Analyst Count | 6 |
| Mean Target | USD 62.67 |
| High Target | USD 70 |
| Low Target | USD 58 |
| Buy / Hold / Sell | 6 / 0 / 0 |
Earnings (COAG)
| Next Earnings Date | 2026-11-10 |
|---|---|
| EPS Estimate | USD -0.52 |
| Revenue Estimate | $0 |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-06-30 | USD -0.8 vs est -0.82 ▲ beat |
Source: Nexqual, November 10, 2026 at 12:21 UTC.
Financials & Fundamentals (COAG)
| Gross Margin | +0.00% |
|---|---|
| Operating Margin | +0.00% |
| Profit Margin | +0.00% |
| Debt / Equity | 0 |
| Current Ratio | 35.85 |
| Total Cash | $457.46M |
| Total Debt | $1.03M |
Source: Nexqual, November 10, 2026 at 12:21 UTC.
Financial Health Score (COAG)
Nexqual rates Hemab Therapeutics Holdings, Inc.'s overall financial health "Mixed" across five dimensions, as of November 10, 2026 at 12:21 UTC.
| Growth | Mixed — No data |
|---|---|
| Profitability | Weak — Pre-revenue or very early stage |
| Balance Sheet | Strong — $457M cash vs $1M debt, net cash position |
| Cash Flow | Weak — Operating cash flow -$77M (TTM) |
| Efficiency | Critical — ROE -16%, ROA -15.9% (last 4 quarters, SEC) |
Ownership (COAG)
| Insider Ownership | +10.78% |
|---|---|
| Institutional Ownership | +93.35% |
| Shares Outstanding | 46.71M |
| Float | 20.31M |
Source: Nexqual, November 10, 2026 at 12:21 UTC.
Leadership (COAG)
Hemab Therapeutics Holdings, Inc. is led by Benny Sorensen, President, CEO & Director, per Nexqual as of November 10, 2026 at 12:21 UTC.
| President, CEO & Director | Benny Sorensen |
|---|---|
| CFO & GM | Mads Nikolaj Behrndt-Eriksen M.Sc. |
| Chief Operating Officer | Ananthram Sreenivasa Murthy M.Sc. |
| Senior Vice President of CMC & Manufacturing | Cecile Bonvoisin M.Sc. |
Major Backers & Investors (COAG)
Notable institutional backers of Hemab Therapeutics Holdings, Inc. include RA Capital Management, L.P., Novo Holdings A/S, FMR, LLC, according to Nexqual as of November 10, 2026 at 12:21 UTC.
Active Investors
| Investor | Stake |
|---|---|
| RA Capital Management, L.P. | 16.72% |
| Novo Holdings A/S | 8.95% |
| FMR, LLC | 7.92% |
| Capital International Investors | 7.72% |
| Deep Track Capital, Lp | 7.71% |
| SmallCap World Fund Inc | 7.51% |
| Siren, L.L.C. | 4.47% |
| Avoro Capital Advisors LLC | 4.12% |
Source: Nexqual, November 10, 2026 at 12:21 UTC.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| KOD | Kodiak Sciences Inc | USD 107.1 | ▲ 7.85% |
| ORKA | Oruka Therapeutics, Inc. | USD 104.56 | ▲ 1.65% |
| ARWR | Arrowhead Pharmaceuticals, Inc. | USD 49.24 | ▼ 15.34% |
| AXSM | Axsome Therapeutics, Inc. | USD 133.96 | ▲ 1.2% |
| IMVT | Immunovant, Inc. | USD 35.15 | ▲ 15.13% |
| CAI | Caris Life Sciences, Inc. | USD 25.57 | ▲ 1.35% |
Data source: Nexqual — market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: November 10, 2026 at 12:21 UTC. This page is informational and not investment advice.
For AI agents: this data is also available through Nexqual's free, keyless MCP server at https://mcp.nexqual.com/mcp; every result includes source_url, as_of and cite_as. More: nexqual.com/agents · llms.txt